All Headache Articles

Assessing and Treating Migraine in Women and Men

A look at the differences in risk, presentation, and care of migraine between men and women.

FDA Approves First Preventive Treatment for Cluster Headache

gammaCore is the first non-invasive, hand-held medical therapy applied at the neck as a therapy to prevent cluster headache.

The Homebound Adolescent: Managing Chronic Pain Conditions in the Pediatric Population

Clinicians can help to answer tough questions about homeschooling and school absences when a child is living with a chronic painful condition.

Biohaven to Begin Phase 1 Testing of New CGRP BHV-3500

Biohaven has received FDA authorization to dose first subject with BHV-3500, a new third-generation CGRP.

Men With Migraine Likely Have Increased Estradiol Levels

Many biological factors, including sex hormones, have been reported as a major contributor to migraine.

Migraine Game-Changers Announce Latest Data, Research Efforts at AHS

Biohaven, Lilly, and Allergan's new research from the American Headache Society (AHS) meeting.

At Stake: The Possible Long-Term Side Effects of CGRP Antagonists

Headache expert Lawrence Robbins, MD, asks a series of questions clinicians need to address before prescribing the long-awaited CGRP antagonists for migraine prevention.

A New Frontier in Migraine Management: Inside CGRP Inhibitors & Migraine Prevention

In this exclusive roundtable, developers recap the data on their CGRP inhibitors, including Aimovig, the first-ever monoclonal antibodies specifically designed to prevent chronic or episodic migraine.

Meet the Migraine Game-Changers

In this exclusive roundtable, Amgen/Novartis, Allergan, Lilly, and Teva recap the data that is moving their CGRP migraine preventives to the finish line. Introduction to CGRPs by Lawrence Robbins, MD

Migraine Sufferers At High Risk for Sleep Apnea and Other Disorders

Men with chronic migraine have been shown to be at a high risk of sleep apnea and other disorders.

Migraine Treatment Set for Reboot

Amgen, Novartis, Alder, Allergan, BioHaven, Lilly, and Teva are all anticipating FDA approval of their novel anti-CGRP chronic migraine preventive medications in 2018

ODT Formulation in Development for Migraine Treatment

CGRP receptor antagonists have been well tolerated in studies.

Low Risk of Serotonin Syndrome in Concomitant Use of Antidepressants and Triptans

Findings challenge a 2006 FDA advisory, questioning its validity

Understanding the Impact of Migraine

Lilly survey results point to need for new headache and migraine treatments as well as patient education.

Medication Overuse Headache: Inaccurate and Overdiagnosed

Diagnosing medication overuse headache, versus medication overuse, can be a tough task for practitioners. Here's how to differentiate the two.

Recent PPM Issues

January/February 2019

Volume 19, Issue #1

View issue

December 2018

Volume 18, Issue #9

View issue

November 2018

Volume 18, Issue #8

View issue

POLL

For which type of pain are you allowing or encouraging the use of cannabinoids in your clinical practice?

Vertical Health Media, LLC does not, by publication of the advertisements contained herein, express endorsement or verify the accuracy and effectiveness of the products and claims contained therein. Vertical Health Media, LLC disclaims any liability for damages resulting from the use of any product advertised herein and suggests that readers fully investigate the products and claims prior to purchasing. The views of the authors are not necessarily those of Vertical Health Media, LLC.

Practical Pain Management is sent without charge 10 times per year to pain management clinicians in the US.

Use of this website is conditional upon your acceptance of our user agreement.

All Headache Articles

Types of Pain

Recent PPM Issues

POLL

Vertical Health Websites